| Item Type | Name |
|
Academic Article
|
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
|
|
Academic Article
|
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
|
|
Academic Article
|
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
|
|
Concept
|
Proto-Oncogene Proteins c-bcr
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Genes, abl
|
|
Concept
|
CD4-Positive T-Lymphocytes
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
Fusion Proteins, bcr-abl
|
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
|
Academic Article
|
Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid.
|
|
Academic Article
|
Detection of luxol-fast-blue positive cells in human promyelocytic leukemia cell line HL-60.
|
|
Academic Article
|
Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
|
|
Academic Article
|
Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing.
|
|
Academic Article
|
Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Cytokine expression of T cells in chronic myeloid leukemia.
|
|
Academic Article
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
|
Academic Article
|
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.
|
|
Academic Article
|
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
|
|
Academic Article
|
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
|
|
Academic Article
|
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
|
|
Academic Article
|
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
|
|
Academic Article
|
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
|
|
Academic Article
|
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
|
|
Academic Article
|
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
|
|
Academic Article
|
Idarubicin in acute leukemia: results of US trials.
|
|
Academic Article
|
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
|
|
Academic Article
|
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
|
|
Academic Article
|
Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
|
|
Academic Article
|
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
|
|
Academic Article
|
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
|
|
Academic Article
|
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
|
|
Academic Article
|
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
|
|
Academic Article
|
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
|
|
Academic Article
|
ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
|
|
Academic Article
|
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
|
|
Academic Article
|
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
|
|
Academic Article
|
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
|
|
Academic Article
|
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.
|
|
Academic Article
|
The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle.
|
|
Academic Article
|
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
|
|
Academic Article
|
[Pro and con: Aggressive or conventional treatment of chronic myelogenous leukemia. Arguments in favor of aggressive treatment].
|
|
Academic Article
|
[Summary: Therapy of chronic myelogenous leukemia--prognosis].
|
|
Academic Article
|
Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
|
|
Academic Article
|
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
|
|
Academic Article
|
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin.
|
|
Academic Article
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
|
|
Academic Article
|
Functional expression of TRAIL by lymphoid and myeloid tumour cells.
|
|
Academic Article
|
Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.
|
|
Academic Article
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
|
Academic Article
|
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
|
Academic Article
|
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
|
|
Academic Article
|
Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.
|
|
Academic Article
|
Acanthamoeba meningoencephalitis after bone marrow transplantation.
|
|
Academic Article
|
Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
|
|
Academic Article
|
Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis.
|
|
Academic Article
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
|
|
Academic Article
|
Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization.
|
|
Academic Article
|
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
|
|
Academic Article
|
Detection and quantitation of BCR-ABL transcripts using a comprehensive quantitative rtpcr analysis system for minimal residual disease in CML patients
|
|
Academic Article
|
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
|
|
Academic Article
|
Dual tel-abl fusion in a PH-negative chronic myeloid leukemia patient
|
|
Academic Article
|
Differential expression of bcr/abl mRNA as determined by in situ amplification as s marker of disease progression in CMLs
|
|
Academic Article
|
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
|
|
Academic Article
|
New directions in the biology and therapy of chronic myeloid leukemia
|
|
Academic Article
|
Treatment of philadelphia chromosome positive (ph +) chronic myelogenous leukemia in blast crisis and ph + acute leukemia with high dose cytosine arabinoside (HDARAC)
|
|
Academic Article
|
Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).
|
|
Academic Article
|
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
|
|
Academic Article
|
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
|
|
Academic Article
|
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
|
|
Academic Article
|
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
|
|
Academic Article
|
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
|
|
Academic Article
|
Loss of expression of both miR-15/16 loci in CML transition to blast crisis.
|
|
Academic Article
|
Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy.
|
|
Academic Article
|
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
|